论文部分内容阅读
目的:探讨多巴酚丁胺联合辛伐他汀治疗肺心病顽固性心衰的临床效果与安全性。方法:100例肺心病顽固性心衰患者,随机分为治疗组与对照组各50例,对照组在心电监护下静脉应用辛伐他汀治疗,治疗组在此基础上加用多巴酚丁胺静脉应用治疗。结果:与对照组相比,治疗组的左室射血分数及每搏输出量有明显的提高(P<0.05)。综合疗效评价,治疗组临床有效率明显高于对照组(P<0.05)。结论:多巴酚丁胺联合辛伐他汀治疗肺心病顽固性心衰可明显的提高血液动力学效应,改善临床症状。
Objective: To investigate the clinical efficacy and safety of dobutamine combined with simvastatin in the treatment of refractory heart failure with pulmonary heart disease. Methods: One hundred patients with refractory heart failure of pulmonary heart disease were randomly divided into treatment group (50 cases) and control group (n = 50). The control group received simvastatin intravenously under electrocardiographic monitoring. The treatment group was given dobutamine Application of intravenous therapy. Results: Compared with the control group, the left ventricular ejection fraction and stroke volume of the treatment group were significantly increased (P <0.05). The comprehensive efficacy evaluation, the clinical effective rate was significantly higher in the treatment group than in the control group (P <0.05). CONCLUSION: Dobutamine and simvastatin can significantly improve the hemodynamic response and improve the clinical symptoms of refractory heart failure caused by pulmonary heart disease.